Clinical Experience in Germany of Treating Community-acquired Respiratory Infections with the New 8-Methoxyfluoroquinolone, Moxifloxacin

Author： Landen H Möller M Tillotson GS Kubin R Höffken G

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.29, Iss.2, 2001-03, pp. : 51-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Moxifloxacin: A Review of its Clinical Potential in the Management of Community-Acquired Respiratory Tract Infections

By Barman Balfour J.A. Lamb H.M.

Drugs, Vol. 59, Iss. 1, 2000-01 ,pp. : 115-139

Adis International

Access to resources Recommend Favorite

Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections

By Hammerschlag Margaret R Sharma Roopali

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 387-400

Informa Healthcare

Access to resources Recommend Favorite

Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin

By Nicolau David P

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 2, 2004-02 ,pp. : 229-235

Informa Healthcare

Access to resources Recommend Favorite

Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections

By Sahloff Eric G Close Sandy J Martin Steven J

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 9, 2002-09 ,pp. : 1251-1266

Informa Healthcare

Access to resources Recommend Favorite

Clarithromycin extended-release in community-acquired respiratory tract infections

By Williams Kathy N Bishai William R

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2867-2876

Informa Healthcare

Access to resources Recommend Favorite